ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics

April 15, 1977

NCI’s Schneiderman Reports Result Of Better Treatment, Some Drop In Incidence, Overall Increase As Kennedy Hearings Open

March 9, 1979

New NCAB Chair Seeks Ideas, Opinions On Cancer Priorities

September 23, 1994

NCI Director May Alert Cancer Panel to Freeze On GS-13 Promotion

November 4, 1994

How to Become a Urology Millionaire…Alas, One Little Problem—Overtreatment

April 13, 2012

Genetic Risk Factor Implicated In Prostate Cancer In Blacks

August 25, 2006